Original ArticleNon–Small Cell Lung CancerImpact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
Cited by (0)
Disclosure: Dr. Voong has received grants from the Lung Cancer Research Foundation and the Radiation Oncology Institute; and has received personal fees from ASCO Advantage. Dr. Forde has received grants from Bristol-Myers Squibb, Astra Zeneca, and Novartis. Dr. Ettinger has received grants from Golden Biotech Corp.; and has received personal fees from BeyondSpring Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co., Genentech, and Guardant Health, Inc. Dr. Marrone has received personal fees from Astra Zeneca and Takeda. Dr. Kelly has received grants from Bristol-Myers Squibb, Eli Lilly, and Astra Zeneca; and has been on the advisory boards of Astellas and Novartis. Dr. Hann has received grants from Merrimack Pharmaceutical; and has received personal fees from Bristol-Myers Squibb, Genentech, AbbVie, and Ascentage. Dr. Levy has received personal fees from Astra Zeneca, Celgene, Eli Lilly, Genentech, and Takeda. Dr. Brahmer has received grants from Bristol-Myers Squibb, and Astra Zeneca/MedImmune; and has received personal fees from Genentech. Dr. Feller-Kopman has received personal fees from Astra Zeneca, Veracyte, and Veran Medical. Dr. Naidoo has received grants from Astra Zeneca and Merck; and has received personal fees from Bristol-Myers Squibb, Astra Zeneca, and Takeda. The remaining authors declare no conflict of interest.